Nationwide screening for Fabry disease in unselected stroke patients
- PMID: 34905550
- PMCID: PMC8670679
- DOI: 10.1371/journal.pone.0260601
Nationwide screening for Fabry disease in unselected stroke patients
Abstract
Background and aims: Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by disease-associated variants in the alpha-galactosidase A gene (GLA). FD is a known cause of stroke in younger patients. There are limited data on prevalence of FD and stroke risk in unselected stroke patients.
Methods: A prospective nationwide study including 35 (78%) of all 45 stroke centers and all consecutive stroke patients admitted during three months. Clinical data were collected in the RES-Q database. FD was diagnosed using dried blood spots in a stepwise manner: in males-enzymatic activity, globotriaosylsphingosine (lyso-Gb3) quantification, if positive followed by GLA gene sequencing; and in females GLA sequencing followed by lyso-Gb3.
Results: 986 consecutive patients (54% men, mean age 70 years) were included. Observed stroke type was ischemic 79%, transient ischemic attack (TIA) 14%, intracerebral hemorrhage (ICH) 7%, subarachnoid hemorrhage 1% and cerebral venous thrombosis 0.1%. Two (0.2%, 95% CI 0.02-0.7) patients had a pathogenic variant associated with the classical FD phenotype (c.1235_1236delCT and p.G325S). Another fourteen (1.4%, 95% CI 0.08-2.4) patients had a variant of GLA gene considered benign (9 with p.D313Y, one p.A143T, one p.R118C, one p.V199A, one p.R30K and one p.R38G). The index stroke in two carriers of disease-associated variant was ischemic lacunar. In 14 carriers of GLA gene variants 11 strokes were ischemic, two TIA, and one ICH. Patients with positive as compared to negative GLA gene screening were younger (mean 60±SD, min, max, vs 70±SD, min, max, P = 0.02), otherwise there were no differences in other baseline variables.
Conclusions: The prevalence of FD in unselected adult patients with acute stroke is 0.2%. Both patients who had a pathogenic GLA gene variant were younger than 50 years. Our results support FD screening in patients that had a stroke event before 50 years of age.
Conflict of interest statement
The authors have read the journal’s policy and have the following competing interests: Takeda (formerly Shire) awarded a grant to the Czech Medical Society of J.E. Purkyně with primary investigator AT. AT, JPS, PR, GD, AL have received speaker’s fees from Takeda. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.
Similar articles
-
Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing.Mol Genet Metab. 2025 May;145(1):109082. doi: 10.1016/j.ymgme.2025.109082. Epub 2025 Mar 15. Mol Genet Metab. 2025. PMID: 40138980
-
The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.Orphanet J Rare Dis. 2022 May 16;17(1):199. doi: 10.1186/s13023-022-02319-4. Orphanet J Rare Dis. 2022. PMID: 35578305 Free PMC article.
-
[Screening Test of Fabry Disease in Patients with Renal Replacement Therapy in the City of Modena].G Ital Nefrol. 2018 Mar;35(2):2018-vol2. G Ital Nefrol. 2018. PMID: 29582965 Italian.
-
Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies.Circ Genom Precis Med. 2023 Dec;16(6):e004252. doi: 10.1161/CIRCGEN.123.004252. Epub 2023 Dec 4. Circ Genom Precis Med. 2023. PMID: 38047356
-
Screening for Fabry disease in a series of Parkinson's disease patients and literature review.Neurol Sci. 2023 Apr;44(4):1235-1241. doi: 10.1007/s10072-022-06554-2. Epub 2022 Dec 22. Neurol Sci. 2023. PMID: 36547780 Review.
Cited by
-
Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms.Int J Mol Sci. 2024 Nov 14;25(22):12252. doi: 10.3390/ijms252212252. Int J Mol Sci. 2024. PMID: 39596318 Free PMC article. Review.
-
Missed diagnosis of Fabry disease: should we screen patients with multiple sclerosis?Neurol Sci. 2024 Jan;45(1):231-239. doi: 10.1007/s10072-023-06962-y. Epub 2023 Jul 22. Neurol Sci. 2024. PMID: 37480392 Free PMC article.
-
Systematic cascade screening in the Danish Fabry Disease Centre: 20 years of a national single-centre experience.PLoS One. 2022 Nov 16;17(11):e0277767. doi: 10.1371/journal.pone.0277767. eCollection 2022. PLoS One. 2022. PMID: 36383556 Free PMC article.
-
Magnitude of the Potential Screening Gap for Fabry Disease in Manitoba: A Population-Based Retrospective Cohort Study.Can J Kidney Health Dis. 2023 Mar 20;10:20543581231162218. doi: 10.1177/20543581231162218. eCollection 2023. Can J Kidney Health Dis. 2023. PMID: 36970566 Free PMC article.
-
Expanding the Neurological Phenotype of Anderson-Fabry Disease: Proof of Concept for an Extrapyramidal Neurodegenerative Pattern and Comparison with Monogenic Vascular Parkinsonism.Cells. 2024 Jun 29;13(13):1131. doi: 10.3390/cells13131131. Cells. 2024. PMID: 38994983 Free PMC article. Review.
References
-
- Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al.. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Human Genetics: Springer; Berlin Heidelberg; 2017. p. 665–77. doi: 10.1007/s00439-017-1779-6 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical